Journal Basic Info
- Impact Factor: 1.995**
- H-Index: 8
- ISSN: 2474-1647
- DOI: 10.25107/2474-1647
Major Scope
- Vascular Surgery
- Obstetrics Surgery
- Cardiovascular Surgery
- Oral and Maxillofacial Surgery
- Endocrine Surgery
- Otolaryngology - Head and Neck Surgery
- Emergency Surgery
- Ophthalmic Surgery
Abstract
Citation: Clin Surg. 2022;7(1):3476.Case Report | Open Access
An Extraordinary Case of Recurring LN-Metastatic Papillary Thyroid Cancer
Beatrix Neururer1*#, Lorenza Scarpa1*#, Gianpaolo Di Santo1, Henrik Einspieler1, Rupert Prommegger2 and Irene J Virgolini1
1Department of Nuclear Medicine, Medical University Innsbruck, Austria
2Department of Visceral and General Surgery, Sanatorium Kettenbrücke Innsbruck, Austria
#These authors contributed equally to this work
*Correspondance to: Beatrix Neururer
PDF Full Text DOI: 10.25107/2474-1647.3476
Abstract
Papillary Thyroid Cancer (PTC) is a differentiated thyroid cancer and also the most common subtype. The incidence, according to expanding use of imaging techniques, biopsy procedures (mostly fineneedle aspiration) and medical surveillance, along with improved access to healthcare, in the last decades are increased; nevertheless the prognosis is very good, with a life expectancy of 85% after 20 years from thyroidectomy. Almost 15% are more aggressive and can metastasize. Up to 50% PTC spread to cervical lymph nodes but distant metastases (primarily lungs or bone) are very rare. Following surgery, including lymphadenectomy, in case of multifocal localized microcarcinoma (stage pT1a (m)) or up to extensive stage (≥ pT1b) after a positive radioactive iodine uptake scans, therapy with 131I-Nal Radioiodine (RAI) is the most common and effective therapy option. However, PTC may lose the ability to absorb radioiodine and alternative treatment options (such as (re-) surgery, Tyrosinkinase Inhibitors (TKI)) are suitable according to a multidisciplinary decision.
Keywords
Cite the article
Neururer B, Scarpa L, Di Santo G, Einspieler H, Prommegger R, Virgolini IJ. An Extraordinary Case of Recurring LN-Metastatic Papillary Thyroid Cancer. Clin Surg. 2022; 7: 3476..